Basem M William

Summary

Affiliation: Case Western Reserve University
Country: USA

Publications

  1. doi request reprint Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma
    Basem M William
    Division of Oncology Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska Electronic address
    Biol Blood Marrow Transplant 20:536-42. 2014
  2. doi request reprint Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma
    Basem M William
    Department of Internal Medicine Division of Oncology Hematology, University of Nebraska Medical Center, Omaha, NE, USA
    Clin Lymphoma Myeloma Leuk 13:417-23. 2013
  3. doi request reprint International analysis of the frequency and outcomes of NK/T-cell lymphomas
    Basem M William
    Department of Medicine, Division of Hematology and Hematology, University Hospitals Seidman Cancer Center, Case Western Reserve University, 11100 Euclid Ave LKS 5079, Cleveland, OH 44106, USA
    Best Pract Res Clin Haematol 26:23-32. 2013
  4. doi request reprint Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients
    Paolo F Caimi
    Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio Case Comprehensive Cancer Center, Cleveland, Ohio Electronic address
    Biol Blood Marrow Transplant 21:1926-31. 2015
  5. doi request reprint Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies
    Basem M William
    Department of Medicine Division of Hematology and Oncology and Stem Cell Transplant Program, University Hospitals Seidman Center and Case Western Reserve University, Cleveland, OH, USA
    Drugs Aging 30:373-81. 2013
  6. pmc Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment
    Manuel Afable
    Clinical Trials Unit, University Hospitals Seidman Cancer Center, Cleveland, Ohio
    Biol Blood Marrow Transplant 21:1529-31. 2015
  7. doi request reprint Trends and Disparities in Cardiovascular Mortality Among Survivors of Hodgkin Lymphoma
    Sadeer G Al-Kindi
    Onco cardiology program, Harrington Heart and Vascular Institute, and Seidman Cancer Center, University Hospitals, Cleveland, OH School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
    Clin Lymphoma Myeloma Leuk 15:748-52. 2015
  8. doi request reprint I-131 tositumomab
    Basem M William
    Oncology Hematology, University of Nebraska Medical Center, Omaha, NE 68198 7680 USA
    Expert Opin Biol Ther 10:1271-8. 2010
  9. ncbi request reprint Small lymphocytic lymphoma in a patient with CREST syndrome
    Basem M William
    University of Nebraska Medical Center and Omaha Veterans Affairs Medical Center, Omaha, Nebraska 68198 7680, USA
    Hematol Oncol Stem Cell Ther 4:132-5. 2011

Collaborators

Detail Information

Publications9

  1. doi request reprint Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma
    Basem M William
    Division of Oncology Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska Electronic address
    Biol Blood Marrow Transplant 20:536-42. 2014
    ..Determining relative efficacy of V-BEAM compared to BEAM would require a randomized trial...
  2. doi request reprint Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma
    Basem M William
    Department of Internal Medicine Division of Oncology Hematology, University of Nebraska Medical Center, Omaha, NE, USA
    Clin Lymphoma Myeloma Leuk 13:417-23. 2013
    ..No prospective trials have compared the effect of different conditioning regimens on outcomes...
  3. doi request reprint International analysis of the frequency and outcomes of NK/T-cell lymphomas
    Basem M William
    Department of Medicine, Division of Hematology and Hematology, University Hospitals Seidman Cancer Center, Case Western Reserve University, 11100 Euclid Ave LKS 5079, Cleveland, OH 44106, USA
    Best Pract Res Clin Haematol 26:23-32. 2013
    ..This review aims to describe the difference in frequency and outcomes for various subtypes of PTCL based on these studies...
  4. doi request reprint Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients
    Paolo F Caimi
    Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio Case Comprehensive Cancer Center, Cleveland, Ohio Electronic address
    Biol Blood Marrow Transplant 21:1926-31. 2015
    ..Prospective studies are needed to confirm whether intensification of conditioning regimens for autologous HCT can improve disease control in high-risk relapsed lymphoma patients. ..
  5. doi request reprint Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies
    Basem M William
    Department of Medicine Division of Hematology and Oncology and Stem Cell Transplant Program, University Hospitals Seidman Center and Case Western Reserve University, Cleveland, OH, USA
    Drugs Aging 30:373-81. 2013
    ..Here we review the current results of SCT in elderly patients, focusing on the role of RIC, and using myeloid diseases as the model for discussion...
  6. pmc Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment
    Manuel Afable
    Clinical Trials Unit, University Hospitals Seidman Cancer Center, Cleveland, Ohio
    Biol Blood Marrow Transplant 21:1529-31. 2015
    ..5 days (range, 7 to 35), respectively. BV before high-dose chemotherapy-ASCT did not adversely affect peripheral blood stem cell mobilization and subsequent engraftment in a cohort of heavily pretreated patients with CD30(+) lymphomas...
  7. doi request reprint Trends and Disparities in Cardiovascular Mortality Among Survivors of Hodgkin Lymphoma
    Sadeer G Al-Kindi
    Onco cardiology program, Harrington Heart and Vascular Institute, and Seidman Cancer Center, University Hospitals, Cleveland, OH School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
    Clin Lymphoma Myeloma Leuk 15:748-52. 2015
    ..HL survivors at greatest risk for cardiovascular death have not been clearly identified. We sought to report trends of CVM identify HL survivors at highest risk...
  8. doi request reprint I-131 tositumomab
    Basem M William
    Oncology Hematology, University of Nebraska Medical Center, Omaha, NE 68198 7680 USA
    Expert Opin Biol Ther 10:1271-8. 2010
    ..I-131 tositumomab is a radiommunoconjugate of (131)I and the anti-CD20 monoclonal antibody tositumomab. It is one of two available radioimmunoconjugates for the treatment of recurrent, refractory, or transformed FL...
  9. ncbi request reprint Small lymphocytic lymphoma in a patient with CREST syndrome
    Basem M William
    University of Nebraska Medical Center and Omaha Veterans Affairs Medical Center, Omaha, Nebraska 68198 7680, USA
    Hematol Oncol Stem Cell Ther 4:132-5. 2011
    ..To our knowledge, there are no reports of a small lymphocytic lymphoma (SLL) in association with limited cutaneous systemic sclerosis with classic features of the CREST syndrome...